Does Latisse Lack Sufficient Safety Stats?

Does Latisse Lack Sufficient Safety Stats? featured image

By now, you’ve probably seen the Latisse commercial enough times to easily recite Brooke Shields‘s possible-side-effects monologue. The FDA, however, feels that the safety information that appears on the prescription eyelash-enhancer’s corresponding website isn’t enough to adequately educate consumers.

Last week, the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a letter to Allergan, the pharmaceutical company behind Latisse, citing the “stark contrast” between latisse.com‘s efficacy statistics and risk information. At the time of the letter’s release, the organization declared that the warning display “fails to present risk information with a prominence and readability reasonably comparable with the presentation of information relating to the effectiveness of the drug.”

Latisse, which contains a prostaglandin (fatty acid derivative) called bimatoprost to grow longer and darker eyelashes, can cause hair growth outside the intended treatment area and bacterial contamination-two risks that the FDA says are omitted or minimized on the site. Additionally, the FDA has accused Allergan of downplaying the potential for infection and increased iris pigment, as well as providing misleading information about allergic reactions.

Allergan is expected to respond to the FDA complaints by September 24.

Have you tried Latisse? Were you completely familiar with the risks before using it? Have the results been worth the possible side effects? Tell us by leaving a comment below.

Related Posts

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.